Expert Review of Anti-Infective Therapy

Article	Citations
The efficacy and safety of complement C5a inhibitors for patients with severe COVID-19: a systematic review and meta-analysis	135
Challenges in preserving antibiotic effectiveness: time for a novel approach	90
Sulbactam-durlobactam for the treatment of Acinetobacter baumannii-calcoaceticus complex	66
Neonatal ocular prophylaxis in the United States: is it still necessary?	57
Visceral leishmaniasis elimination in India: progress and the road ahead	53
A narrative review on drug development for the management of antimicrobial- resistant infection crisis in Japan: the past, present, and future	48
Optic and peripheral neuropathy associated with short and prolonged administration of tedizolid: a review	45
Emerging issues on Staphylococcus aureus endocarditis and the role in therapy of daptomycin plus fosfomycin	43
Part 1: Understanding the role of Malassezia spp. in skin disorders: Malassezia yeasts as commensal or pathogenic organisms of human and a	38
Nontuberculous mycobacterial pulmonary disease and the potential role of SPR720	38
The efficacy and safety of ceftolozane-tazobactam in the treatment of GNB infections: a systematic review and meta-analysis of clinical studies	38
The emergence of Japanese encephalitis as a public health concern in New South Wales Australia	38
A multicenter study of antibiotic resistance patterns of bacterial isolates from patients with hematological and solid cancers	37
The global surge of drug-resistant infections and what it reveals about our failing defenses	37
Recent updates in treating carbapenem-resistant infections in patients with hematological malignancies	36
Tackling antimicrobial resistance in sub-Saharan Africa: challenges and opportunities for implementing the new people-centered WHO guidelines	35
Response to: ‘letter to the editor: “A multifaceted strategy is needed to limit the over-the-counter sale of antimicrobials “’	35
Can inhaled antifungals provide a viable solution for treatment-refractory pulmonary fungal infections?	34
Difficile to treat: advanced management strategies in difficult to treat Clostridioides difficile infections	34
Current status of immunomodulatory therapies in adult sepsis patients: where do we stand?	32
Can Saccharomyces cerevisiae be used as a therapeutic agent for vulvovaginal candidiasis?	29
Tineas caused by hedgehogs due to Trichophyton erinacei an ascending agent of dermatophytosis	28
Decoding drug resistance in Mycobacterium tuberculosis complex: genetic insights and future challenges	27
New and emerging roles for inhalational and direct antifungal drug delivery approaches for treatment of invasive fungal infections	27
Treatment of vaginitis caused by non-albicans Candida species	27

Identifying predictors of treatment failure with community-acquired pneumonia: an update	26
Reemergence of monkeypox: prevention and management	25
Hypoalbuminemia as a predictor of severe dengue: a systematic review and meta-analysis	25
Safety and efficacy of Paxlovid in the treatment of adults with mild to moderate COVID-19 during the omicron epidemic: a multicentre study from China	24
Advances and controversies in the diagnosis and management of neurocysticercosis: a clinical perspective	23
Treatment of pulmonary mucormycosis: current concepts	23
Phage- and enzybiotic-coated urinary catheters to prevent recurrent multidrug-resistant bacterial infections	22
Advances in therapeutic strategies against Mycobacterium marinum infection	21
The ongoing challenge of prevention of pertussis in infants: what’s new in 2024?	21
Direct or early Discharge of Acute Bacterial Skin and Skin Structure Infection patients from the Emergency Department/Unit: place in therapy of dalbavancin	21
Iatrogenic factors of Helicobacter pylori eradication failure: lessons from the frontline	20
Analysis of bacterial spectrum and construction of a predictive model for postoperative sepsis in patients with upper urinary calculi and positive urinary cultures	20
Diagnostic and clinical management of Candida auris infections in immunocompromised patients	20
Impact of a clinical engagement targeted antimicrobial stewardship program on antimicrobial use in Pakistan: a multicenter longitudinal point prevalence survey	20
Infliximab as a potential treatment for COVID-19	20
Diagnostic and management strategies for chronic hepatitis E infection	19
Healthcare professionals’ understanding and perception of drug-related issues linked to off-label pharmacological medications used for COVID-19	19
Clinical efficacy of nirmatrelvir plus ritonavir in patients with COVID-19 and preexisting cardiovascular diseases	19
Predicting the limit to ceftriaxone’s use in gonorrhea treatment: impending resistance and logistical challenges	19
One health and resistant fungi: a challenging balancing act between food security and patient survival	18
Real-world effectiveness and tolerability of post solid organ transplant patients with CMV switching from valganciclovir treatment to maribavir: analysis using lab-linked claims data in the United Sta	17
Effectiveness of recently-approved oral antiviral medications on the outcome of patients with mild-to-moderate COVID-19 and pre–existing chronic obstructive pulmonary diseases	17
Anti-inflammatory and immunomodulatory effects of mesenchymal stem cell therapy on parasitic drug resistance	17
Updates on Candida albicans infections: pathogenesis, resistance, and emerging nanopharmaceutical strategies	16
Perceptions and preparedness of senior medical students about antimicrobial stewardship programs: are we providing adequate training to future prescribers?	16
Understanding host responses to equine encephalitis virus infection: implications for therapeutic development	16
Nintedanib: a review of the properties, function, and usefulness to minimize COVID-19-induced lung injury	16
Statement of Retraction	16
Theranostic nanomaterials for scalp and hair fungal infections: advancing diagnosis and treatment amidst challenges	16
Correction	16
Oteseconazole: a long-awaited diversification of the antifungal arsenal to manage recurrent vulvovaginal candidiasis (RVVC)	16
The serological dilemma: rethinking syphilis treatment evaluation	15
Risk of HIV viral rebound after SARS-CoV-2 infection among people living with HIV on antiretroviral therapy: a retrospective matched cohort study	15
Selling antibiotics without prescriptions among community pharmacies and drug outlets: a simulated client study from Ghana	15
Challenges, risks, and opportunities of antiretroviral drugs in women of reproductive potential	15
In vitro and in vivo activity of meropenem+avibactam against MBL-producing carbapenem-resistant Klebsiella pneumoniae	15
The opportunities and challenges of epigenetic approaches to manage herpes simplex infections	15
Low-risk penicillin allergy delabeling: a scoping review of direct oral challenge practice, implementation, and multi-disciplinary approaches	14
Inhibiting horizontal gene transfer to contain antimicrobial resistance: conjugation and plasmid maintenance as druggable targets	14
New advances in management and treatment of multidrug-resistant Klebsiella pneumoniae	14
Diagnosing fungal infections in clinical practice: a narrative review	14
Interaction of zincite, alpha-terpineol, geranyl acetate, linalool, myrcenol, terpinolene, and thymol with virulence factors of Escherichia coli, Mycobacterium tuberculosis, Pseudomonas	13
Ceftazidime-avibactam and aztreonam combination for Carbapenem-resistant Enterobacterales bloodstream infections with presumed Metallo-β-lactamase production: a systemat	13
Monoclonal antibodies for the treatment of COVID-19 infection in children	13
Predictors and patterns of empirical antibiotic therapy and associated outcomes in COVID-19 patients: a retrospective study in a tertiary care facility in South India	13
Monotherapy versus combination for the treatment of Stenotrophomonas maltophilia: a multicenter cohort study	13
The evolving debate around screening for Chlamydia trachomatis	13
Investigating forthcoming strategies to tackle deadly superbugs: current status and future vision	12
Interrupting HIV transmission networks: how can we design and implement timely and effective interventions?	12
Precision antibiotic treatment in intensive care unit-acquired lower respiratory tract infections (ICU-LRTIs): contemporary concepts and future directions	12

Targeted screening for HTLV-1 infection in endemic and non-endemic regions: a global public health priority	12
Exploring thresholds and interaction effects among antibiotic usage, covariates, and their effect on antibiotic resistance using an extended-spectrum β-Lactamase–producing Klebsiella pneumoniae	12
Real-world discontinuations due to neuropsychiatric symptoms in people living with HIV treated with second-generation integrase inhibitors: a systematic review	12
An overview of potential combination therapies with ceftriaxone as a treatment for gonorrhoea	12
How can we tackle the overuse of antibiotics in low- and middle-income countries?	12
Challenges associated with pertussis detection, monitoring, and vaccination in adults	12
Immunomodulatory markers and therapies for the management of infant respiratory syncytial virus infection	12
Disruptive innovation in antibiotic development: a vision for lysins	12
Clinical utility of procalcitonin in implementation of procalcitonin-guided antibiotic stewardship in the South-East Asia and India: evidence and consensus-based recommendations	12
Comparison of effectiveness and safety of nirmatrelvir/ritonavir versus sotrovimab for COVID-19: a systematic review and meta-analysis	11
Contemporary pharmacologic treatments of MRSA for hospitalized adults: rationale for vancomycin versus non-vancomycin therapies as first line agents	11
Practices, Knowledge, and Attitudes of Nephrologists Towards Prescribing and Monitoring Vancomycin at Dialysis Centers	11
Clinical outcomes, virological efficacy and safety of nitazoxanide in the treatment of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials	11
Phage therapy: resurrecting a historical solution for the contemporary challenge of rising antibiotic resistance in Latin America	11
Tocilizumab for the treatment of COVID-19	11
Unmet targets: evaluating vancomycin use and predictive factors of target attainment in hemodialysis patients	11
The evolving scenario of HCV-related mixed cryoglobulinemia and B-cell lymphoma in the era of direct-acting antivirals	11
A 96-week efficacy and safety of BIC/FTC/TAF in ART-naïve HIV-1 infected patients in China	11
Vitamin D attenuates biofilm-associated infections via immunomodulation and cathelicidin expression: a narrative review	11
How do we best manage Clostridioides difficle infections in the elderly?	11
Gram-positive infections in special populations. Expert view on the role of dalbavancin	11
Now that griseofulvin is not available, what to do with tinea capitis treatments?	10
Clinical efficacy of probiotics in the treatment of patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials	10
Nirmatrelvir and ritonavir combination: an antiviral therapy for COVID-19	10
New insights into the treatment of acute otitis media	10
Comparison of clinical outcomes of antibiotics used for Staphylococcus aureus bacteremia in pediatric patients	10
Diagnosis of urinary tract infections in the pediatric population – current practices, advances and progress	10
Could Herpesviridae be the cause of severe acute hepatitis of unknown origin in children?	10
Real-life effectiveness of antiviral therapy for HCV infection with pangenotypic regimens in HIV coinfected patients	10
Comparative effectiveness of ceftaroline plus vancomycin or daptomycin versus vancomycin or daptomycin monotherapy for MRSA bacteremia: an updated systematic review and meta-analysis	10
Understanding mechanisms of virulence in MRSA: implications for antivirulence treatment strategies	9
Update on actinomycetoma treatment: linezolid in the treatment of actinomycetomas due to Nocardia spp and Actinomadura madurae resistant t	9
The effect of combination antibiotic therapy on mortality in patients with sepsis or septic shock due to Pseudomonas aeruginosa bloodstream infections: a	9
Synergistic effect of eravacycline combined with fluconazole against resistant Candida albicans in vitro and in vivo	9
Artificial intelligence and prescription of antibiotic therapy: present and future	9
Metallo-beta-lactamases: mechanisms, treatment challenges, and future prospects	9
An update on newer antifungals	9
Women trailblazers shaping the global future of antimicrobial stewardship and antimicrobial resistance	9
Efficacy and safety of gepotidacin versus standard of-care antibiotics for the treatment of uncomplicated urogenital infections in adults and adolescents: a systematic review and meta-analysis	9
Public knowledge of antibiotics, self-medication, and household disposal practices in Jordan	9
Global importance of new treatment strategies to efforts to control hepatitis B virus	9
Effect of tixagevimab/cilgavimab for pre-exposure prophylaxis during the China Omicron outbreak	8
Introduction and spread of NDM-producing Enterobacterales and Acinetobacter baumannii into Middle Eastern countries: a molecular-based hypothesis	8
The prevalence of antimicrobial drug resistance of non-typhoidal Salmonella in human infections in sub-Saharan Africa: a systematic review and meta-analysis	8
Lenacapavir: a twice-yearly treatment for adults with multidrug-resistant HIV infection and limited treatment options	8
Host defense mechanisms against Candida auris	8
Risk factors for colistin-resistant, extensively drug-resistant (XDR) and pandrug-resistant (PDR) Acinetobacter baumannii infections: a review	8
An update on antimicrobial selection and duration for intra-abdominal infections	8
Efficacy and safety of eravacycline (ERV) in treating infections caused by Gram-negative pathogens: a systematic review and meta-analysis	8
Tracing the recent updates on vaccination approaches and significant adjuvants being developed against HIV	8
Lack of knowledge of antibiotic risks among outpatients is associated with intention to use antibiotics without a prescription	8
How can the use of digital molecular diagnostic tools help to tackle malaria?	8
Unveiling the potential role of micro/nano biomaterials in the treatment of Helicobacter pylori infection	8
Past, present, and future perspectives on aztreonam and avibactam	8
Nucleos(t)ide analogue treatment in hepatitis B: to stop or not to stop?	8
High frequency and molecular characterization of ESBL-producing Enterobacteriaceae isolated from wound infections in North Lebanon	7
HTLV-I associated bronchioloalveolar disorder (HABA): disease concept and differential diagnosis of an unsolved disease entity	7
Non-cancerous complications in HTLV-1 carriers	7
Effectiveness of bundles to prevent surgical site infections in cranial neurosurgery: systematic review, meta-analysis, and GRADE evaluation	7
Management of invasive fungal infections in the intensive care unit	7
Wide-spectrum antibiotic prophylaxis guarantees optimal outcomes in drowned donor kidney transplantation	7
Brincidofovir in the Era of Mpox	7
Rifampicin in periprosthetic joint infections: where do we stand and where are we headed?	7
Safety and efficacy of new generation azole antifungals in the management of recalcitrant superficial fungal infections and onychomycosis	7
Treatment of cryptosporidiosis: nitazoxanide yes, but we can do better	7
The potential of 4D’s approach in curbing antimicrobial resistance among bacterial pathogens	7
Critical reappraisal of current issues for improving the proper clinical use of the incoming beta-lactam/beta-lactamase inhibitor combinations of tomorrow	7
Current evidence of bulevirtide as monotherapy compared to combination treatment with pegylated interferon for hepatitis delta	7
Can probiotics replace antibiotics? Not yet, says the evidence	7
Analysis of clinical characteristics and prognostic factors of ARDS caused by community-acquired pneumonia in people with different immune status	7
Antibiofilm and antimicrobial activity of curcumin-chitosan nanocomplexes and trimethoprim-sulfamethoxazole onAchromobacter, Burkholderia, andStenotrophomonasisolates	7
Indian consensus on the management of carbapenem-resistant enterobacterales infection in critically ill patients II (ICONIC II)	7
HIV postnatal prophylaxis: how long is long enough?	6
From guesswork to guidelines: advancing diagnostic stewardship in immunocompromised hosts	6
The impact of gender inequities on antimicrobial resistance in low-income countries: a comprehensive review	6
Analysis of policies for use of medically important antibiotics in animals in Namibia: implications for antimicrobial stewardship	6
Genomic surveillance of Neisseria gonorrhoeae : a crucial tool in the global fight against antimicrobial resistance	6
Comparative efficacy and safety of antiviral traditional Chinese medicine injections for viral pneumonia: a systematic review and network meta-analysis	6
Prevalence of antibiotic resistance in clinical isolates of Mycobacterium kansasii : a systematic review and meta-analysis	6
Letermovir for cytomegalovirus infection in allogeneic hematopoietic stem-cell transplantation: tips and notes for effective use in clinical practice	6

Mechanisms of resistance to cell wall and plasma membrane targeting antifungal drugs in Candida species isolated in Africa	6
Real-world implementation of dolutegravir plus lamivudine in people living with HIV in Southwest China	6
Association of outpatient fluoroquinolone prescribing with the National Medical Products Administration announcements of label changes in China	6
Economic impact of managing invasive mold disease with isavuconazole compared with liposomal amphotericin B followed by posaconazole in Spain	6
Update on the diagnosis, pathophysiology and treatment strategies in non-HIV-associated cryptococcal meningoencephalitis	6
Continuous infusion of beta-lactam antibiotics: narrative review of systematic reviews, and implications for outpatient parenteral antibiotic therapy	6
Current perspectives of bacteriophage therapy for multidrug-resistant wound infections	6
Omadacycline in treating community-based infections: a review and expert perspective	6
Management of calcified cysticerci in the brain parenchyma: treating the dead parasite	6
How do we change our approach to COVID with the changing face of disease?	6
A plain language summary of the safety and effectiveness of isavuconazole for the treatment of serious fungal disease in children with a weakened immune system	6
Langya henipavirus outbreak	6
Clinical effectiveness of oral antivirals for non-hospitalized adult COVID-19 patients aged 18–60 years	6
Current overview of health technologies for antimicrobial resistance (AMR) management in hospitals: a scoping review, bibliometric analysis and technological prospecting	5
Development of antiviral drugs for COVID-19 in 2025: unmet needs and future challenges	5
Evaluating long-acting injectable HIV treatment: an update on cabotegravir and rilpivirine	5
Candida auris biofilm: a review on model to mechanism conservation	5
Advantages and limitations of current diagnostic laboratory approaches in syphilis and congenital syphilis	5
HCV treatment in Sardinian HIV-HCV coinfected patients: a real-life perspective study on safety, efficacy, and immune reconstitution	5
Factors associated with treatment failure, and possible applications of probiotic bacteria in the arsenal againstHelicobacter pylori	5
An evaluation of sipavibart for pre-exposure prophylaxis of COVID-19 in immunocompromised individuals	5
Surgical site infections after vascular surgery – current strategies and future directions	5
The future of non-invasive azole antifungal treatment options for the management of vulvovaginal candidiasis	5
Asymptomatic is not silent: proposal of HTLV-1-associated multiple inflammatory disorder as an early neuroinflammatory state	5
Evaluation of duration of antibiotic therapy across hospitals in Scotland including the impact of COVID-19 pandemic: a segmented interrupted time series analysis	5
Artificial intelligence and its application in clinical microbiology	5
COVID-19 convalescent plasma safety and efficacy analysis for biologics license application approval	5
Antibiotic resistance in low- and middle-income countries: current practices and its global implications	5
Phage therapy: innovations, challenges, and future directions in combating superbugs and antibiotic resistance	5
The efficacy and safety of hydroxychloroquine at different doses and courses for COVID-19 prevention: a systematic review and network meta-analysis	5
Typical and atypical clinical profiles in syphilis patients: will genotyping of syphilis agents and patients help to explain symptom differences?	5
Letter to the Editor: the earliest observation of bla NDM was in Israel	5
A multifaceted strategy is needed to limit the over-the-counter sale of antimicrobials	5
Nirmatrelvir/ritonavir: real world drug–drug interaction management experience	5
Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) in Canada: treatment update and the role of new IV antimicrobials	5
Ursodeoxycholic acid and COVID-19 outcomes: a cohort study and data synthesis of state-of-art evidence	5
Letter to the editor: “real-life effectiveness of antiviral therapy for HCV infection with pangenotypic regimens in HIV coinfected patients”	5
Why do we urgently need a new treatment for cerebral aspergillosis?	5
Tixagevimab/cilgavimab for prevention and treatment of COVID-19: a review	5
Doxycycline post-exposure prophylaxis as prevention of STIs – the golden bullet?	4
Treatment strategies for OXA-48-like and NDM producing Klebsiella pneumoniae infections	4
Biosimilars as antivirals: opportunities and challenges	4
Continuous care engagement in clinical practice: perspectives on selected current strategies for people with HIV in the United States	4
The effectiveness of novel oral antiviral treatment for non-hospitalized high-risk patients with COVID-19 during predominance of omicron XBB subvariants	4
Therapeutic strategies to address monkeypox	4
Complicated urinary tract infections: evolving definitions, clinical burden, and treatment landscape amid antimicrobial resistance	4
Penile microbiomes have important implications for HIV susceptibility and broader reproductive health	4
Updates in the clinical management of tuberculous meningitis	4
Interplay between the arachidonic acid/cyclooxygenase 2/prostaglandin E 2 pathway and RNA viral infections	4
Visited India? Metronidazole may not cure your Giardia infection	4
Comparison of dolutegravir+Lamivudine and bictegravir/emtricitabine/tenofovir alafenamide in antiretroviral therapy-naïve patients infected with HIV: preliminary results from clinical practice	4
Adverse effects of antibiotics in children with cancer: are short-course antibiotics for febrile neutropenia part of the solution?	4
Carbapenem-resistant Klebsiella pneumoniae : the role of plasmids in emergence, dissemination, and evolution of a major clinical challenge	4
Sepsis management in the antimicrobial resistance era	4
New therapeutic strategies for Mycobacterium abscessus pulmonary diseases – untapping the mycolic acid pathway	4
Personalized care approaches to hepatitis C therapy: recent advances and future directions	4
Antimicrobial management of complex biofilms in diabetic foot ulcers: a microbiological perspective	4
From Data to Decisions: Leveraging Large, Real-World Databases to Guide Clinical Practice in C. difficile Infections	4
What is the impact of SARS-CoV-2 infection during pregnancy on child immunity?	4
The endocarditis team: a review	4
Febrile neutropenia management in high-risk neutropenic patients: a narrative review on antibiotic prophylaxis and empirical treatment	4
Androgen receptor, a possible anti-infective therapy target and a potent immune respondent in SARS-CoV-2 spike binding: a computational approach	4
The antifungal pipeline for invasive fungal diseases: what does the future hold?	4
Metabolic outcomes of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir/lamivudine in treatment-naïve people living with HIV: a 48-week retrospective study	4
Impact of nirmatrelvir/ritonavir on the risk of long COVID in outpatients: a systematic review and meta-analysis	4
Part 1: Mucormycosis: prevalence, risk factors, clinical features, and diagnosis	4
Immunocompromised patients and COVID-19: how do we protect those most at risk?	4
Concerns with current Drug Laws regarding the purchasing antibiotics without a prescription in Pakistan; ways forward to assist the national action plan	4
Part 2: Understanding the role of Malassezia spp. in skin disorders: pathogenesis of Malassezia associated skin infections	4
Escalation of antimicrobial resistance among MRSA part 1: focus on global spread	4
Developing AWaRe-ness in primary care across low- and middle-income countries – a vital challenge for antibiotic stewardship programs	4
The impacts of the national centralized drug procurement policy on the use of policy-related antibiotic agents: the case of Shaanxi province, China	4
Could the next disease X be pandemic of virus-induced encephalitis? what should be our first medical response?	4